Drug
ADV/HSV-tk plus valacyclovir
Drug Profile
| Therapeutic Class | Gene Therapy |
| Drug Class | Gene Therapy |
| Group | Gene Therapy |
| Mechanism of Action | Gene Therapy |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Construct-dependent, often intentionally radiation-enhancing (suicide gene/prodrug, RT-inducible promoters, immune-gene delivery) (Advani et al. Journal of Clinical Oncology 2007; Vlachaki et al. International Journal of Radiation Oncology, Biology, Physics 2001; Marco et al. Cancer Cell 2026). Adverse events likewise depends on the construct—tumor-targeted/RT-inducible expression aims to spare normal tissue, whereas immune-gene approaches carry a theoretical local/systemic inflammatory adverse event risk.
Data on this page refer exclusively to patients treated with
ADV/HSV-tk plus valacyclovir combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Gene Therapy group page.